As 2016 approaches, it is an important time to look back on 2015 and all that the year entailed for stem cell advances. During 2016, I was honored to have interviewed a number of key thought leaders in the stem cell space, including the CEO of the largest dental stem cell company in the world (Tony Veverka of BioEden), Chief Business Officer for a company creating the world’s largest blood cell repository for iPSC production (James Lovgren of ORIG3N), and VP of Research and Development for one of the most innovative companies operating within the stem cell sector (Dr. Grynspan of Stem Cell Medicine).
Throughout 2015, my team and I conducted dozens of other interviews as well, with stem cell executives, investors, and researchers. These interviews were published on our stem cell industry blog and also informed market projections for BioInformant’s stem cell and cord blood market intelligence reports.
Below are the top five stem cell interviews of 2015, based on total number of page views, number of unique page views, and total number of social shares. Congratulations to the five individuals listed here!
In early 2016, we will be releasing a series of new stem cell interviews, including one with the CEO of Gamida Cell and one with the CEO of Accellta. To access these upcoming interviews, sign-up below.
Top 5 Stem Cell Interviews of 2015
[#1 of 5] TOP STEM CELL INTERVIEW OF 2015: Jim Lovgren, Chief Business Officer of ORIG3N
[#2 of 5] 2ND STEM CELL INTERVIEW OF 2015: Dr. Frida Grynspan, VP of Research and Development for Stem Cell Medicine
[#3 of 5] 3RD STEM CELL INTERVIEW OF 2015: Tony Veverka, CEO of BioEden
[4th of 5] 4TH STEM CELL INTERVIEW OF 2015: Kyle Cetrulo, CEO of Auxocell
[5th of 5] 5TH STEM CELL INTERVIEW OF 2015: Dr. Ornella Parolini, President of the International Placenta Stem Cell Society (IPLASS)
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Becton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.